RxDoctor Payments Data

Lisa Morgan

Nurse Practitioner · Hattiesburg, MSNPI 1487631461

Payments from drug & device makers

$1,757in general payments, 2019–2025

Across 28 payments — averaging $62.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$293
  • Axsome Therapeutics, Inc.$288
  • Johnson & Johnson$198
  • AstraZeneca$172
  • Otsuka America Pharmaceutical, Inc.$148
  • Teva Pharmaceuticals USA, Inc.$140
  • plus $519 from 10 others

What the payments were for

  • Food & beverage$1,757100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,757 in reported general payments places this provider in the 80th percentile of 1,090 nurse practitioner providers in Mississippi.

See all nurse practitioner providers in Mississippi

Medicare billing

Part B allowed, 2024
$43,989
Medicare patients
163
Services billed
346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate16$51,676
Ziprasidone Hcl18$2,454
Buspirone Hcl185$1,906
Sertraline Hcl229$1,898
Olanzapine135$1,797
Quetiapine Fumarate166$1,715
Oxcarbazepine37$1,561
RivastigmineRivastigmine Tartrate12$1,118
Clozapine14$1,096
Haloperidol34$1,029
Trazodone Hcl121$1,005
Mirtazapine50$831
Divalproex Sodium47$798
Risperidone61$714
Benztropine Mesylate41$405

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$198$51,67616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,090 nurse practitioner providers in Mississippi.

Other nurse practitioner in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →